MedTrace Logo

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-08-24

No results posted yet for this study

Summary

Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage III/Stage IV melanoma.

Conditions

  • Malignant Melanoma

Interventions

DRUG

ACY-241

tablet

DRUG

nivolumab

infusion

DRUG

ipilimumab

infusion

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • ApoCell, Inc.

    collaborator INDUSTRY

  • Celerion

    collaborator INDUSTRY

  • NYU Langone Health

    collaborator OTHER

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Jeffrey S Weber · Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center

  • Elizabeth Buchbinder · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-04-07
Completion
2017-04-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935790 on ClinicalTrials.gov